Promising
Berberine
The prediction game
Call it: rising or fading?
Where does Berberine stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 6.8/10
Berberine is a 6.8 / 10 fit for people considering blood sugar, metabolic health, cardiovascular, liver detox, with the strongest case in the populations already represented by the evidence rather than broad wellness use. [Liu 2025](https://pubmed.ncbi.nlm.nih.gov/40740996/) and [Li 2024](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309144) give the report its main anchors, while the score stays worth trying because benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. Berberine makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat Berberine as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place. ✅ Best for: Adults with diagnosed type 2 diabetes, prediabetes, metabolic syndrome, elevated triglycerides, insulin-resistant PCOS, or NAFLD who want an adjunctive metabolic tool and can monitor labs. Berberine is especially relevant when metformin is not tolerated or accessible, but it should not replace clinician-directed diabetes care. It also fits selected short-course gut protocols, including H. pylori-adjacent regimens like Chen 2023, and possibly ulcerative-colitis adjunct care under GI supervision per Li 2024. ❌ Avoid if: You are pregnant, breastfeeding, trying to conceive without clinician guidance, caring for a neonate, jaundiced, or using transplant drugs, anticoagulants, CYP-sensitive psychiatric medications, macrolides, cyclosporine, tacrolimus, warfarin, DOACs, or complex polypharmacy without pharmacist clearance. Avoid berberine if you are metabolically healthy and chasing weight loss, generic longevity, or "nature's Ozempic" claims. EFSA's 2026 draft process also makes EU users a wait-and-see group until the final safety position is clear.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
In the news this week: Jay Campbell.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Promising
- Trend
- Begins with Edition 2
- Momentum
- 15.8%
- BioHarmony Score
- 6.8/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.